Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Coussens LM, Fingleton B, Matrisian LM.

Science. 2002 Mar 29;295(5564):2387-92. Review.

PMID:
11923519
2.

Matrix metalloproteinase inhibitors as anticancer therapeutics.

Mannello F, Tonti G, Papa S.

Curr Cancer Drug Targets. 2005 Jun;5(4):285-98. Review.

PMID:
15975049
3.

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.

Zucker S, Cao J, Chen WT.

Oncogene. 2000 Dec 27;19(56):6642-50. Review.

4.

Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?

Mannello F.

Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):91-103. Review.

PMID:
18221029
5.

Progress in the development of matrix metalloproteinase inhibitors.

Tu G, Xu W, Huang H, Li S.

Curr Med Chem. 2008;15(14):1388-95. Review.

PMID:
18537616
6.

Development of matrix metalloproteinase inhibitors in cancer therapy.

Hidalgo M, Eckhardt SG.

J Natl Cancer Inst. 2001 Feb 7;93(3):178-93. Review.

PMID:
11158186
7.

Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?

Rudek MA, Venitz J, Figg WD.

Pharmacotherapy. 2002 Jun;22(6):705-20. Review.

PMID:
12066962
8.

Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.

Fingleton B.

Expert Opin Ther Targets. 2003 Jun;7(3):385-97. Review.

PMID:
12783574
9.

[Expression of matrix metalloproteinases in patients with malignant tumors].

Stanciūte D, Didziapetriene J, Kadziauskas J.

Medicina (Kaunas). 2004;40(12):1143-50. Review. Lithuanian.

10.

[Metalloproteinases in tumor progression. Review].

Arvelo F, Cotte C.

Invest Clin. 2006 Jun;47(2):185-205. Review. Spanish.

PMID:
16886780
11.

Matrix metalloproteinase inhibitors: current developments and future perspectives.

Hoekstra R, Eskens FA, Verweij J.

Oncologist. 2001;6(5):415-27. Review.

12.

Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.

Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC.

Expert Opin Investig Drugs. 2001 Jun;10(6):1075-84. Review.

PMID:
11772236
14.

Matrix metalloproteinases as therapeutic targets in cancer.

Vihinen P, Ala-aho R, Kähäri VM.

Curr Cancer Drug Targets. 2005 May;5(3):203-20. Review.

PMID:
15892620
15.

Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.

Folgueras AR, Pendás AM, Sánchez LM, López-Otín C.

Int J Dev Biol. 2004;48(5-6):411-24. Review.

16.

Biological activity and clinical implications of the matrix metalloproteinases.

Rydlova M, Holubec L Jr, Ludvikova M Jr, Kalfert D, Franekova J, Povysil C, Ludvikova M.

Anticancer Res. 2008 Mar-Apr;28(2B):1389-97. Review.

17.

The other side of MMPs: protective roles in tumor progression.

Martin MD, Matrisian LM.

Cancer Metastasis Rev. 2007 Dec;26(3-4):717-24. Review.

PMID:
17717634
18.

Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies.

Chau I, Rigg A, Cunningham D.

Crit Rev Oncol Hematol. 2003 Feb;45(2):151-76. Review.

PMID:
12604127
19.

Matrix metalloproteinase inhibitors as anticancer agents.

Konstantinopoulos PA, Karamouzis MV, Papatsoris AG, Papavassiliou AG.

Int J Biochem Cell Biol. 2008;40(6-7):1156-68. doi: 10.1016/j.biocel.2007.11.007. Epub 2007 Nov 22. Review.

PMID:
18164645
20.

Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Hu J, Van den Steen PE, Sang QX, Opdenakker G.

Nat Rev Drug Discov. 2007 Jun;6(6):480-98. Review.

PMID:
17541420

Supplemental Content

Support Center